PSIL Soars on 32x Volume as Atai Beckley Jumps

AdvisorShares Psychedelics ETF (PSIL) has seen unusual trading volume, which is 32× higher than its average daily volume.

The ETF’s largest holding, Atai Beckley N.V., is in focus after multiple analysts reiterated Buy ratings and sharply higher price targets, while the stock also rallied alongside the broader sector on a new White House executive order that speeds FDA reviews and funding for psychedelic therapies and supports its BPL-003 program heading toward Phase 3. Compass Pathways, another top weight, gained attention as analysts reaffirmed bullish views with high upside targets and the company expanded its U.S. delivery strategy for COMP360 through a new collaboration with Osmind, positioning it to benefit from priority review vouchers under the same executive order. Definium Therapeutics, GH Research, NRx Pharmaceuticals, Alto Neuroscience, and Helus Pharma all welcomed the policy shift and reported positive analyst commentary or pipeline milestones, including Definium’s upcoming Investor Day and DT120 Phase 3 updates, GH Research’s planned global Phase 3 program for GH001, NRx’s ketamine-based strategy, Alto’s new Phase 2b depression trial, and Helus’s leadership change and Phase 3 HLP003 program, collectively underscoring a more supportive regulatory and funding backdrop for PSIL’s core holdings.